Home | Medical-Newswire.Com:
(Medical-NewsWire.com, March 12, 2022 ) The Brazil Cancer Therapy market size is estimated to reach $1.9 billion by 2027, growing at a CAGR of 8.1% during the forecast period 2022-2027. Cancer therapy involves the use of surgical or non-surgical procedures for the treatment of various cancers. A patient suffering from cancer can receive many different types of therapies, including treatment designed for reducing cancer symptoms, such as pain and fatigue. Some of the commonly used therapeutic procedures for cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation therapy. Few of the most prevalent cancer types in Brazil include breast cancer, prostate cancer, lung cancer, and colorectum cancer. The rapid rise in the geriatric population is anticipated to drive the market during the forecast period. However, the COVID-19 pandemic is projected to hamper the number of cancer diagnostic and therapeutic procedures conducted during the forecast period.
Brazil Cancer Therapy Market Segment Analysis – By Cancer Type
Based on Cancer Type, the Brazil Cancer Therapy Market is segmented into Blood Cancer, Bone Cancer, Skin Cancer, Breast Cancer, Colorectal Cancer, Oral Cancer, Gastrointestinal Cancer, Prostate Cancer, Kidney Cancer, Endocrine Cancer, Respiratory Cancer, and Others. The prostate cancer segment is anticipated to have the largest share of the market in 2021 and is poised to dominate the market during the forecast period 2022-2027. This is attributed to the high prevalence of prostate cancer among the Brazilian population. According to the World Health Organization (WHO), prostate cancer accounted for nearly 16.4% of all new cancer cases in 2020. Moreover, prostate cancer accounted for more than 32.4% of cancer cases among males in 2020. The prostate cancer segment is also projected to grow the fastest at a CAGR of 8.8% owing to the rising geriatric population in Brazil.
Brazil Cancer Therapy Market Segment Analysis – By Treatment Type
The Brazil Cancer Therapy Market based on Treatment Type can be further segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, and Other Treatment Types. The Chemotherapy segment accounted for the largest share of the market in 2021. Chemotherapy involves the use of one or a combination of multiple anti-cancer drugs to destroy cancer cells. The treatment can be given with curative intent, or it may be used to suppress symptoms and increase patient lifespan. Chemotherapy treatment is most commonly performed via intravenous injection. However, they can also be taken as a pill, capsule, cream or liquid by mouth. The targeted therapy segment is anticipated to witness the fastest growth at a CAGR of 9.0% during the forecast period owing to their ability to alter proteins within cancer cells that cause those cells to die.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=18401
Report Price: $ 4300 (Single User License)
Brazil Cancer Therapy Market Drivers
Increase in Geriatric Population is Projected to Drive Market Growth.
The proportion of the elderly population in Brazil has grown significantly since 1950. For instance, the geriatric population in 1950 was only around 2.6 million, representing about 4.9% of the population. In 2020, the elderly population reached 30.1 million, representing about 14.3% of the population. Moreover, it is estimated that the geriatric population will reach 73.4 million by 2060. This is anticipated to drive the market for cancer therapy as the geriatric population is more susceptible to cancers. For instance, the median age for the diagnosis of prostate cancer is 66 years. Meanwhile, the median age is 67 years for colorectal cancer and 71 years for lung cancer.
The rise in Lifestyle disorders is Anticipated to Boost Demand
Owing to the growth in disposable income and urbanization in Brazil, more people are following a sedentary lifestyle. This is causing an increase in lifestyle diseases such as obesity and hypertension among the population. For instance, obesity rates increased from only 12.2% in 2003 to around 22.1% in 2021. Moreover, the proportion of the population who are overweight increased from 43.3% in 2003 to 61.7% in 2019. Besides, it is estimated that nearly 40.7% of Brazilians suffer from hypertension. This is driving the demand as obesity and hypertension are major risk factors of cancer.
Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=18401
Brazil Cancer Therapy Market Challenges
The High Cost of Cancer Therapy is Anticipated to Hamper Market Growth
The high cost of cancer therapy is a major challenge that can hamper market growth. According to the US National Institute of Health (NIH), the annual mean cost per patient for cancer therapy in Brazil was $9,572.3, varying from $5,782.1 for breast cancer to $16,656 for cervical cancer. This can make high-quality cancer therapy inaccessible to the vast majority of the population as the average per capita income of the country is estimated to be only around $14,550 in 2020. Besides, even though Brazil provides free public healthcare, the waiting period for medical services can be extremely long as the facilities are often oversubscribed.
COVID-19 Pandemic and Subsequent Restrictions is Projected to Limit Growth Opportunities
The rapid spread of the Covid-19 virus and the rising patient hospitalizations have increased the stress faced by the Brazilian healthcare system. This is challenging the market growth as hospitals are forced to divert funds from other departments including oncology in order to procure essential equipment such as ventilators, PPE kits, masks, ICU beds, and oxygen concentrators for combating the pandemic. At least 22 million people were infected and more than 611,000 people died from the virus. Moreover, the fear of contracting the virus from the hospital environment is causing patients to cancel diagnostic and treatment appointments, further contributing to the decrease in market growth.
Brazil Cancer Therapy Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Brazil Cancer Therapy Market. The top 10 companies of the industry include:
F. Hoffmann-La Roche
In December 2020, Servier do Brazil, a Servier Group affiliate announced the launch of their first oncology treatment in the solid tumor field on the Brazilian market. This launch follows the obtention, by Servier do Brazil, of the market authorization delivered on May 2020 by the Brazilian Health Regulatory Agency (ANVISA).
In September 2020, Samsung Bioepis announced the launch of their trastuzumab biosimilar Ontruzant in Brazil for the treatment of breast and gastric cancer. Samsung Bioepis’ biosimilar trastuzumab is sold under the trade name Ontruzant and they will be sold in 150 mg single-dose vial.
Based on cancer type, the prostate cancer segment accounted for the largest share of the market in 2021 owing to their high prevalence among the Brazilian population.
The rapid rise in awareness among the Brazilian population regarding the importance of early detection and treatment of cancer is driving the market during the forecast period. However, the high cost of cancer therapy is projected to challenge market growth.
Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Brazil Cancer Therapy Market Report.
A. Cancer Hormone Therapy Market
B. LATAM Oncology Drugs Market
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.